The ability to predict which lung cancer patients will respond to immunotherapy could transform treatment decisions for thousands of patients annually. Current response rates hover around 20-30%, leaving many patients enduring toxic treatments without benefit while potentially missing more effective alternatives.
This investigation analyzed paired tumor and adjacent tissue samples from non-small cell lung cancer patients using advanced sequencing techniques to map both microbial communities and gene expression patterns. The analysis revealed that healthy adjacent tissues contained significantly more diverse bacterial populations than tumor tissues themselves. Two specific bacterial genera—Bradyrhizobium and Prevotella—emerged as particularly influential in the paracancerous regions, showing strong correlations with immune cell activity including CD8+ T cells, natural killer cells, and activated dendritic cells.
Crucially, patients with higher levels of Prevotella in their paracancerous tissues demonstrated both improved overall survival and better responses to immune checkpoint inhibitor therapy across multiple independent patient cohorts. Bradyrhizobium showed immune associations but lacked the prognostic power.
This research advances our understanding of the tumor microbiome's role beyond the digestive tract, suggesting that local bacterial communities directly influence cancer immunity. The findings could lead to microbiome-based biomarkers for treatment selection, potentially sparing non-responders from ineffective immunotherapy while identifying optimal candidates. However, the observational nature means causation remains unclear—whether these bacteria directly enhance immune responses or simply reflect healthier tissue environments. The field needs validation studies and mechanistic research to determine if microbiome modification could actively improve immunotherapy outcomes.